Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.

Journal of neuro-oncology·2026
Same author

Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models.

PloS one·2025
Same author

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.

Cell reports. Medicine·2025
Same author

Disruption of ataxia telangiectasia-mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models.

The Journal of clinical investigation·2025
Same author

Social pain: A systematic review on interventions.

F1000Research·2025
Same author

A clinically relevant model and method to study necrosis as a driving force in glioma restructuring and progression.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Apr 5, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.7K

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.

Katherine L Misuraca1, Francisco J Cordero2, Oren J Becher3

  • 1Department of Pediatrics, Division of Hematology-Oncology, Duke University Medical Center , Durham, NC , USA.

Frontiers in Oncology
|August 11, 2015
PubMed
Summary

Diffuse intrinsic pontine glioma (DIPG) research is advancing through improved animal and cell models. These models are crucial for understanding DIPG and developing new treatments for this rare childhood brainstem tumor.

Keywords:
DIPGbrainstem gliomapre-clinical animal models

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

4.0K

Related Experiment Videos

Last Updated: Apr 5, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.7K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

4.0K

Area of Science:

  • Pediatric neuro-oncology
  • Cancer modeling
  • Brain tumor research

Background:

  • Diffuse intrinsic pontine glioma (DIPG) is a rare, incurable pediatric brainstem tumor.
  • Current treatment (radiation) has seen no significant advances in 30 years.
  • Lack of effective models hinders understanding and treatment development.

Purpose of the Study:

  • To review progress in modeling DIPG.
  • To highlight the importance of improved models for therapeutic development.
  • To discuss the potential of novel preclinical models for DIPG treatment.

Main Methods:

  • Review of animal models (allograft, xenograft) using non-DIPG cells.
  • Development of in vitro and in vivo models from patient autopsy material and stem cells.
  • Summary of genetically engineered mouse models for DIPG.

Main Results:

  • Initial animal models provided a basis for DIPG research.
  • Patient-derived and stem cell-derived models offer improved biological relevance.
  • Genetically engineered mouse models are advancing DIPG understanding.

Conclusions:

  • Improved DIPG models are critical for unraveling gliomagenesis mechanisms.
  • Cooperative use of diverse models will accelerate preclinical testing of novel therapeutics.
  • Advancements in modeling hold promise for future DIPG patient treatments.